2016
DOI: 10.1182/blood-2015-09-672030
|View full text |Cite
|
Sign up to set email alerts
|

The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases

Abstract: • Cell-free (plasma) EBV DNA performs better than cellular EBV DNA as a marker of a broad range of EBV 1 diseases.• Within a largely immunocompromised and hospitalized cohort, detection of EBV DNA in plasma is uncommon in the absence of EBV 1 disease.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

9
132
3
2

Year Published

2016
2016
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 169 publications
(146 citation statements)
references
References 40 publications
9
132
3
2
Order By: Relevance
“…by guest www.bloodjournal.org From prognosis. [15][16][17][18] Strong PDL1 expression correlated with excellent responses. 13 The low-dose pembrolizumab regimen (2 mg/kg) 7 was not associated with significant adverse events, even after allo-HSCT, consistent with safety of immune-checkpoint blockade after allo-HSCT.…”
Section: Pembrolizumab In Refractory Nk/t-cell Lymphomas 2441mentioning
confidence: 99%
“…by guest www.bloodjournal.org From prognosis. [15][16][17][18] Strong PDL1 expression correlated with excellent responses. 13 The low-dose pembrolizumab regimen (2 mg/kg) 7 was not associated with significant adverse events, even after allo-HSCT, consistent with safety of immune-checkpoint blockade after allo-HSCT.…”
Section: Pembrolizumab In Refractory Nk/t-cell Lymphomas 2441mentioning
confidence: 99%
“…Latent Epstein–Barr virus (EBV) can induce malignancies such as lymphoma and nasopharyngeal carcinoma . Lo et al .…”
Section: Can Ctdna Be Used In Cancer Screening Programmes In Definedmentioning
confidence: 99%
“…With the rapid development of real-time quantitative PCR, the measurement of EBV DNA load (EDL) during these EBV-associated diseases has been largely implemented in clinical practice (3)(4)(5). The monitoring of EDL in blood is required for transplant recipients at risk of posttransplantation lymphoproliferative disorders (PTLDs) and could also be a surrogate marker for the adjustment of the immunosuppressive regimen in these patients (6,7).…”
mentioning
confidence: 99%